The Global Market for HPV Associated Disorders, 2018-2023 and 2024-2033, Featuring Profiles of Leading Players AstraZeneca, Roche, Biocon, GlaxoSmithKline, and Merck & Co
19. April 2024 10:59 ET
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "HPV Associated Disorders Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global HPV associated disorders...
Cervical Intraepithelial Neoplasia Pipeline Research Report 2023: Insights into More than 8 Companies and Over 10 Pipeline Drugs
16. Oktober 2023 10:43 ET
|
Research and Markets
Dublin, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Cervical...
Global Human Papilloma Virus (HPV) Research Report 2023: Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecasts 2015-2033
25. August 2023 06:08 ET
|
Research and Markets
Dublin, Aug. 25, 2023 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Market Size by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast to...
Global CIN & HR-HPV Treatment Market Forecast Report 2022-2023 & 2028: Use of Modern Technologies in CIN & HR-HPV Screening and Diagnosis Gaining Traction
03. Juli 2023 04:33 ET
|
Research and Markets
Dublin, July 03, 2023 (GLOBE NEWSWIRE) -- The "Global CIN & HR-HPV Treatment Market Forecast to 2028 - Analysis by Disease Type, Strain Type, Offering, Product Type, and End-user" report has...
Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria
15. Juni 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001
07. Januar 2016 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...